GeoVax Labs, Inc. (GOVX)
| Market Cap | 30.81M |
| Revenue (ttm) | 1.84M |
| Net Income (ttm) | -2.21M |
| Shares Out | 782,978 |
| EPS (ttm) | -5.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $5.10 |
| Previous Close | $5.40 |
| Change ($) | -0.30 |
| Change (%) | -5.56% |
| Day's Open | 5.34 |
| Day's Range | 4.95 - 5.40 |
| Day's Volume | 361,985 |
| 52-Week Range | 2.56 - 8.71 |
GeoVax (NASDAQ: GOVX) shares are trading sharply higher on Monday after the company announced it was awarded an NIH grant to advance its COVID-19 vaccine development. GeoVax is a U.S.-based cl...
Company Focused on Single-dose Vaccine Against Multiple COVID Strains
GeoVax Also Participating in BIO@JPM During “J.P. Morgan Week 2021”
GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q4 2020 Results - Earnings Call Transcript
GeoVax Labs, Inc.'s (GOVX) CEO David Dodd on Q3 2020 Results - Earnings Call Transcript
Public Offering Completed in September 2020 Provides Resources to Accelerate COVID-19 Vaccine and Immuno-Oncology Programs
Conference call to be held Friday, November 6, at 8:15 a.m. Eastern Time
ATLANTA, GA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapi...
GeoVax Labs (GOVX) news for Monday includes a deal with the National Institutes of Health to develop a vaccine for the novel coronavirus. The post GeoVax Labs News: GOVX Stock Flies 18% on NIH...
Shares of GeoVax Labs Inc. were up 12.8% in trading on Monday after the company announced a patent and material licensing deal with the National Institutes of Health for COVID-19 vaccine devel...
ATLANTA, GA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapie...
ATLANTA, GA, Sept. 29, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunothe...
ATLANTA, GA, Sept. 24, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunoth...
About GOVX
GeoVax Labs, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has ... [Read more...]
| Industry Biotechnology | Founded 2001 |
| CEO David Dodd | Employees 6 |
| Stock Exchange NASDAQ | Ticker Symbol GOVX |
Financial Performance
In 2019, GeoVax Labs's revenue was $1.18 million, an increase of 22.08% compared to the previous year's $963,203. Losses were -$2.37 million, -7.40% less than in 2018.
Analyst Forecasts
According to one analyst, the rating for GeoVax Labs stock is "Buy" and the 12-month stock price forecast is 8.00.